Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document

A. Pieter Kappetein, Stuart J. Head, Philippe Généreux, Nicolo Piazza, Nicolas M. Van Mieghem, Eugene H. Blackstone, Thomas G. Brott, David J. Cohen, Donald E. Cutlip, Gerrit Anne Van Es, Rebecca T. Hahn, Ajay J. Kirtane, Mitchell W. Krucoff, Susheel Kodali, Michael J. Mack, Roxana Mehran, Josep Rodés-Cabau, Pascal Vranckx, John G. Webb, Stephan WindeckerPatrick W. Serruys, Martin B. Leon

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Objectives: The aim of the current Valvular Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic valve implantation (TAVI)- clinical endpoints to make them more suitable to the present and future needs of clinical trials. In addition, this document is intended to expand understanding of patient risk stratification and case selection. Background: A recent study confirmed that VARC definitions have already been incorporated into clinical and research practice and represent a new standard for consistency in reporting clinical outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI. However, as the clinical experience with this technology has matured and expanded, certain definitions have become unsuitable or ambiguous. Methods and results: Two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 2012 in Rotterdam, The Netherlands) involving VARC study group members, independent experts (including surgeons, interventional and non-interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical trialists), the United States Food and Drug Administration (FDA), and industry representatives, provided much of the substantive discussion from which this VARC-2 consensus manuscript was derived. This document also provides an overview of risk assessment and patient stratification that needed to be considered for accurate patient inclusion in studies. Working groups were assigned to define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding, acute kidney injury, vascular complications, conduction disturbances & arrhythmias, and a miscellaneous category including relevant complications not previously categorized. Furthermore, comprehensive echocardiographic recommendations are provided for evaluation of prosthetic valve (dys)function. Definitions for quality of life assessments are also reported. These endpoints formed the basis for several recommended composite endpoints. Conclusions: This VARC-2 document has provided further standardization of endpoint definitions for studies evaluating the use of TAVI, which will lead to improved comparability and interpretability of study results, supplying an increasingly growing body of evidence with respect to transcatheter aortic valve implantation and/or surgical aortic valve replacement. This initiative and document can furthermore be used as a model during current endeavors of applying definitions to other transcatheter valve therapies (for example, mitral valve repair).

Original languageEnglish (US)
Pages (from-to)782-795
Number of pages14
JournalEuroIntervention
Volume8
Issue number7
DOIs
StatePublished - Nov 1 2012

Fingerprint

Research
Manuscripts
Aortic Valve Stenosis
Drug Industry
United States Food and Drug Administration
Aortic Valve
Mitral Valve
Acute Kidney Injury
Surgical Instruments
Geriatrics
Netherlands
Blood Vessels
Transcatheter Aortic Valve Replacement
Cardiac Arrhythmias
Stroke
Myocardial Infarction
Quality of Life
Clinical Trials
Hemorrhage
Technology

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Pieter Kappetein, A. ; Head, Stuart J. ; Généreux, Philippe ; Piazza, Nicolo ; Van Mieghem, Nicolas M. ; Blackstone, Eugene H. ; Brott, Thomas G. ; Cohen, David J. ; Cutlip, Donald E. ; Van Es, Gerrit Anne ; Hahn, Rebecca T. ; Kirtane, Ajay J. ; Krucoff, Mitchell W. ; Kodali, Susheel ; Mack, Michael J. ; Mehran, Roxana ; Rodés-Cabau, Josep ; Vranckx, Pascal ; Webb, John G. ; Windecker, Stephan ; Serruys, Patrick W. ; Leon, Martin B. / Updated standardized endpoint definitions for transcatheter aortic valve implantation : The Valve Academic Research Consortium-2 consensus document. In: EuroIntervention. 2012 ; Vol. 8, No. 7. pp. 782-795.
@article{2f5cb45dad8d40caaa2598e7be5e1522,
title = "Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document",
abstract = "Objectives: The aim of the current Valvular Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic valve implantation (TAVI)- clinical endpoints to make them more suitable to the present and future needs of clinical trials. In addition, this document is intended to expand understanding of patient risk stratification and case selection. Background: A recent study confirmed that VARC definitions have already been incorporated into clinical and research practice and represent a new standard for consistency in reporting clinical outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI. However, as the clinical experience with this technology has matured and expanded, certain definitions have become unsuitable or ambiguous. Methods and results: Two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 2012 in Rotterdam, The Netherlands) involving VARC study group members, independent experts (including surgeons, interventional and non-interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical trialists), the United States Food and Drug Administration (FDA), and industry representatives, provided much of the substantive discussion from which this VARC-2 consensus manuscript was derived. This document also provides an overview of risk assessment and patient stratification that needed to be considered for accurate patient inclusion in studies. Working groups were assigned to define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding, acute kidney injury, vascular complications, conduction disturbances & arrhythmias, and a miscellaneous category including relevant complications not previously categorized. Furthermore, comprehensive echocardiographic recommendations are provided for evaluation of prosthetic valve (dys)function. Definitions for quality of life assessments are also reported. These endpoints formed the basis for several recommended composite endpoints. Conclusions: This VARC-2 document has provided further standardization of endpoint definitions for studies evaluating the use of TAVI, which will lead to improved comparability and interpretability of study results, supplying an increasingly growing body of evidence with respect to transcatheter aortic valve implantation and/or surgical aortic valve replacement. This initiative and document can furthermore be used as a model during current endeavors of applying definitions to other transcatheter valve therapies (for example, mitral valve repair).",
author = "{Pieter Kappetein}, A. and Head, {Stuart J.} and Philippe G{\'e}n{\'e}reux and Nicolo Piazza and {Van Mieghem}, {Nicolas M.} and Blackstone, {Eugene H.} and Brott, {Thomas G.} and Cohen, {David J.} and Cutlip, {Donald E.} and {Van Es}, {Gerrit Anne} and Hahn, {Rebecca T.} and Kirtane, {Ajay J.} and Krucoff, {Mitchell W.} and Susheel Kodali and Mack, {Michael J.} and Roxana Mehran and Josep Rod{\'e}s-Cabau and Pascal Vranckx and Webb, {John G.} and Stephan Windecker and Serruys, {Patrick W.} and Leon, {Martin B.}",
year = "2012",
month = "11",
day = "1",
doi = "10.4244/EIJV8I7A121",
language = "English (US)",
volume = "8",
pages = "782--795",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "7",

}

Pieter Kappetein, A, Head, SJ, Généreux, P, Piazza, N, Van Mieghem, NM, Blackstone, EH, Brott, TG, Cohen, DJ, Cutlip, DE, Van Es, GA, Hahn, RT, Kirtane, AJ, Krucoff, MW, Kodali, S, Mack, MJ, Mehran, R, Rodés-Cabau, J, Vranckx, P, Webb, JG, Windecker, S, Serruys, PW & Leon, MB 2012, 'Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document', EuroIntervention, vol. 8, no. 7, pp. 782-795. https://doi.org/10.4244/EIJV8I7A121

Updated standardized endpoint definitions for transcatheter aortic valve implantation : The Valve Academic Research Consortium-2 consensus document. / Pieter Kappetein, A.; Head, Stuart J.; Généreux, Philippe; Piazza, Nicolo; Van Mieghem, Nicolas M.; Blackstone, Eugene H.; Brott, Thomas G.; Cohen, David J.; Cutlip, Donald E.; Van Es, Gerrit Anne; Hahn, Rebecca T.; Kirtane, Ajay J.; Krucoff, Mitchell W.; Kodali, Susheel; Mack, Michael J.; Mehran, Roxana; Rodés-Cabau, Josep; Vranckx, Pascal; Webb, John G.; Windecker, Stephan; Serruys, Patrick W.; Leon, Martin B.

In: EuroIntervention, Vol. 8, No. 7, 01.11.2012, p. 782-795.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Updated standardized endpoint definitions for transcatheter aortic valve implantation

T2 - The Valve Academic Research Consortium-2 consensus document

AU - Pieter Kappetein, A.

AU - Head, Stuart J.

AU - Généreux, Philippe

AU - Piazza, Nicolo

AU - Van Mieghem, Nicolas M.

AU - Blackstone, Eugene H.

AU - Brott, Thomas G.

AU - Cohen, David J.

AU - Cutlip, Donald E.

AU - Van Es, Gerrit Anne

AU - Hahn, Rebecca T.

AU - Kirtane, Ajay J.

AU - Krucoff, Mitchell W.

AU - Kodali, Susheel

AU - Mack, Michael J.

AU - Mehran, Roxana

AU - Rodés-Cabau, Josep

AU - Vranckx, Pascal

AU - Webb, John G.

AU - Windecker, Stephan

AU - Serruys, Patrick W.

AU - Leon, Martin B.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objectives: The aim of the current Valvular Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic valve implantation (TAVI)- clinical endpoints to make them more suitable to the present and future needs of clinical trials. In addition, this document is intended to expand understanding of patient risk stratification and case selection. Background: A recent study confirmed that VARC definitions have already been incorporated into clinical and research practice and represent a new standard for consistency in reporting clinical outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI. However, as the clinical experience with this technology has matured and expanded, certain definitions have become unsuitable or ambiguous. Methods and results: Two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 2012 in Rotterdam, The Netherlands) involving VARC study group members, independent experts (including surgeons, interventional and non-interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical trialists), the United States Food and Drug Administration (FDA), and industry representatives, provided much of the substantive discussion from which this VARC-2 consensus manuscript was derived. This document also provides an overview of risk assessment and patient stratification that needed to be considered for accurate patient inclusion in studies. Working groups were assigned to define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding, acute kidney injury, vascular complications, conduction disturbances & arrhythmias, and a miscellaneous category including relevant complications not previously categorized. Furthermore, comprehensive echocardiographic recommendations are provided for evaluation of prosthetic valve (dys)function. Definitions for quality of life assessments are also reported. These endpoints formed the basis for several recommended composite endpoints. Conclusions: This VARC-2 document has provided further standardization of endpoint definitions for studies evaluating the use of TAVI, which will lead to improved comparability and interpretability of study results, supplying an increasingly growing body of evidence with respect to transcatheter aortic valve implantation and/or surgical aortic valve replacement. This initiative and document can furthermore be used as a model during current endeavors of applying definitions to other transcatheter valve therapies (for example, mitral valve repair).

AB - Objectives: The aim of the current Valvular Academic Research Consortium (VARC)-2 initiative was to revisit the selection and definitions of transcatheter aortic valve implantation (TAVI)- clinical endpoints to make them more suitable to the present and future needs of clinical trials. In addition, this document is intended to expand understanding of patient risk stratification and case selection. Background: A recent study confirmed that VARC definitions have already been incorporated into clinical and research practice and represent a new standard for consistency in reporting clinical outcomes of patients with symptomatic severe aortic stenosis (AS) undergoing TAVI. However, as the clinical experience with this technology has matured and expanded, certain definitions have become unsuitable or ambiguous. Methods and results: Two in-person meetings (held in September 2011 in Washington, DC, USA, and in February 2012 in Rotterdam, The Netherlands) involving VARC study group members, independent experts (including surgeons, interventional and non-interventional cardiologists, imaging specialists, neurologists, geriatric specialists, and clinical trialists), the United States Food and Drug Administration (FDA), and industry representatives, provided much of the substantive discussion from which this VARC-2 consensus manuscript was derived. This document also provides an overview of risk assessment and patient stratification that needed to be considered for accurate patient inclusion in studies. Working groups were assigned to define the following clinical endpoints: mortality, stroke, myocardial infarction, bleeding, acute kidney injury, vascular complications, conduction disturbances & arrhythmias, and a miscellaneous category including relevant complications not previously categorized. Furthermore, comprehensive echocardiographic recommendations are provided for evaluation of prosthetic valve (dys)function. Definitions for quality of life assessments are also reported. These endpoints formed the basis for several recommended composite endpoints. Conclusions: This VARC-2 document has provided further standardization of endpoint definitions for studies evaluating the use of TAVI, which will lead to improved comparability and interpretability of study results, supplying an increasingly growing body of evidence with respect to transcatheter aortic valve implantation and/or surgical aortic valve replacement. This initiative and document can furthermore be used as a model during current endeavors of applying definitions to other transcatheter valve therapies (for example, mitral valve repair).

UR - http://www.scopus.com/inward/record.url?scp=84872143850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872143850&partnerID=8YFLogxK

U2 - 10.4244/EIJV8I7A121

DO - 10.4244/EIJV8I7A121

M3 - Article

C2 - 23022744

AN - SCOPUS:84872143850

VL - 8

SP - 782

EP - 795

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 7

ER -